ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Next, we evaluated the treatment response at the early response stage (3 months) after the administration of 400 mg IM in the newly diagnosed CML patients; 4/100 (4%), 34/100 (34%), and 29/100 (29%) failed to achieve complete hematologic response (CHR), complete cytogenetic response (CCR), and optimal molecular response (BCR–ABL1 IS% < 10), respectively.